Dietary Nitrate Supplementation Reduces Circulating Platelet-Derived Extracellular Vesicles in Coronary Artery Disease Patients on Clopidogrel Therapy: A Randomised, Double-Blind, Placebo-Controlled Study

Abstract

Extracellular vesicles (EVs) are implicated in the pathogenesis of cardiovascular disease (CVD). Specifically, platelet-derived EVs are highly pro-coagulant, promoting thrombin generation and fibrin clot formation. Nitrate supplementation exerts beneficial effects in CVD, via an increase in nitric oxide (NO) bioavailability. Clopidogrel is capable of producing NO-donating compounds, such as S-nitrosothiols (RSNO) in the presence of nitrite and low pH. The aim of this study was to assess the effect of nitrate supplementation with versus without clopidogrel therapy on circulating EVs in coronary artery disease (CAD) patients. In this randomized, double-blind, placebo-controlled study, CAD patients with (n = 10) or without (n = 10) clopidogrel therapy received a dietary nitrate supplement (SiS nitrate gel) or identical placebo. NO metabolites and platelet activation were measured using ozone-based chemiluminescence and multiple electrode aggregometry. EV concentration and origin were determined using nanoparticle tracking analysis and time-resolved fluorescence. Following nitrate supplementation, plasma RSNO was elevated (4.7 ± 0.8 vs 0.2 ± 0.5 nM) and thrombin-receptor mediated platelet aggregation was reduced (−19.9 ± 6.0 vs 4.0 ± 6.4 U) only in the clopidogrel group compared with placebo. Circulating EVs were significantly reduced in this group (−1.183e¹¹ ± 3.15e¹⁰ vs −9.93e⁹± 1.84e¹⁰ EVs/mL), specifically the proportion of CD41+ EVs (−2,120 ± 728 vs 235 ± 436 RFU [relative fluorescence unit]) compared with placebo. In vitro experiments demonstrated clopidogrel–SNO can reduce platelet-EV directly (6.209e¹⁰± 4.074e⁹ vs 3.94e¹¹ ±  1.91e¹⁰ EVs/mL). In conclusion, nitrate supplementation reduces platelet-derived EVs in CAD patients on clopidogrel therapy, increasing patient responsiveness to clopidogrel. Nitrate supplementation may represent a novel approach to moderating the risk of thrombus formation in CAD patients.

Keywords

extracellular vesicles - clopidogrel - nitrate - nitrite - nitric oxide

• References

• 1 Zubairova LD, Nabiullina RM, Nagaswami C. , et al. Circulating microparticles alter formation, structure, and properties of fibrin clots. Sci Rep 2015; 5: 17611
• 2 Puddu P, Puddu GM, Cravero E, Muscari S, Muscari A. The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases. Can J Cardiol 2010; 26 (04) 140-145
• 3 Kurachi M, Mikuni M, Ishizaki Y. Extracellular vesicles from vascular endothelial cells promote survival, proliferation and motility of oligodendrocyte precursor cells. PLoS One 2016; 11 (07) e0159158
• 4 Jansen F, Nickenig G, Werner N. Extracellular vesicles in cardiovascular disease: potential applications in diagnosis, prognosis, and epidemiology. Circ Res 2017; 120 (10) 1649-1657
• 5 Sinning J-M, Losch J, Walenta K, Böhm M, Nickenig G, Werner N. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J 2011; 32 (16) 2034-2041
• 6 Aatonen MT, Ohman T, Nyman TA, Laitinen S, Grönholm M, Siljander PR. Isolation and characterization of platelet-derived extracellular vesicles. J Extracell Vesicles 2014; 3: 24692
• 7 Sinauridze EI, Kireev DA, Popenko NY. , et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97 (03) 425-434
• 8 Adamski P, Koziński M, Ostrowska M. , et al. Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb Haemost 2014; 112 (02) 224-242
• 9 Behan MWH, Fox SC, Heptinstall S, Storey RF. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets 2005; 16 (02) 73-80
• 10 Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 2003; 8 (01) 71-86
• 11 Kirkby NS, Lundberg MH, Chan MV. , et al. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci U S A 2013; 110 (39) 15782-15787
• 12 Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008; 7 (02) 156-167
• 13 Velmurugan S, Gan JM, Rathod KS. , et al. Dietary nitrate improves vascular function in patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr 2016; 103 (01) 25-38
• 14 Velmurugan S, Kapil V, Ghosh SM. , et al. Antiplatelet effects of dietary nitrate in healthy volunteers: involvement of cGMP and influence of sex. Free Radic Biol Med 2013; 65: 1521-1532
• 15 Lee DH, Kim MH, Guo LZ. , et al. Concomitant nitrates enhance clopidogrel response during dual anti-platelet therapy. Int J Cardiol 2016; 203: 877-881
• 16 Megson IL, Sogo N, Mazzei FA, Butler AR, Walton JC, Webb DJ. Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy. Br J Pharmacol 2000; 131 (07) 1391-1398
• 17 Bundhoo SS, Anderson RA, Sagan E. , et al. Direct formation of thienopyridine-derived nitrosothiols--just add nitrite!. Eur J Pharmacol 2011; 670 (2–3): 534-540
• 18 James PE, Willis GR, Allen JD, Winyard PG, Jones AM. Nitrate pharmacokinetics: Taking note of the difference. Nitric Oxide 2015; 48: 44-50
• 19 McQuillan JA, Casadio JR, Dulson DK, Laursen PB, Kilding AE. The effect of nitrate supplementation on cycling performance in the heat in well-trained cyclists. Int J Sports Physiol Perform 2017; 19: 1-22
• 20 Kerley CP, Cahill K, Bolger K. , et al. Dietary nitrate supplementation in COPD: an acute, double-blind, randomized, placebo-controlled, crossover trial. Nitric Oxide 2015; 44: 105-111
• 21 Witwer KW, Buzás EI, Bemis LT. , et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles 2013; 2: 20360
• 22 Lacroix R, Judicone C, Mooberry M, Boucekine M, Key NS, Dignat-George F. ; The ISTH SSC Workshop. Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2013; 2: 12207
• 23 Connolly KD, Guschina IA, Yeung V. , et al. Characterisation of adipocyte-derived extracellular vesicles released pre- and post-adipogenesis. J Extracell Vesicles 2015; 4: 29159
• 24 Willis GR, Connolly K, Ladell K. , et al. Young women with polycystic ovary syndrome have raised levels of circulating annexin V-positive platelet microparticles. Hum Reprod 2014; 29 (12) 2756-2763
• 25 Connolly KD, Willis GR, Datta DBN. , et al. Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia. J Lipid Res 2014; 55 (10) 2064-2072
• 26 Webb AJ, Patel N, Loukogeorgakis S. , et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension 2008; 51 (03) 784-790
• 27 Carlström M, Persson AEG, Larsson E. , et al. Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension. Cardiovasc Res 2011; 89 (03) 574-585
• 28 Willis GR, Udiawar M, Evans WD, Blundell HL, James PE, Rees DA. Detailed characterisation of circulatory nitric oxide and free radical indices--is there evidence for abnormal cardiovascular homeostasis in young women with polycystic ovary syndrome?. BJOG 2014; 121 (13) 1596-1603
• 29 Anderson RA, Bundhoo S, James PE. A new mechanism of action of thienopyridine antiplatelet drugs - a role for gastric nitrosthiol metabolism?. Atherosclerosis 2014; 237 (01) 369-373
• 30 Richardson G, Hicks SL, O'Byrne S. , et al. The ingestion of inorganic nitrate increases gastric S-nitrosothiol levels and inhibits platelet function in humans. Nitric Oxide 2002; 7 (01) 24-29
• 31 Liu T, Schroeder HJ, Wilson SM. , et al. Local and systemic vasodilatory effects of low molecular weight S-nitrosothiols. Free Radic Biol Med 2016; 91: 215-223
• 32 Ingram TE, Pinder AG, Bailey DM, Fraser AG, James PE. Low-dose sodium nitrite vasodilates hypoxic human pulmonary vasculature by a means that is not dependent on a simultaneous elevation in plasma nitrite. Am J Physiol Heart Circ Physiol 2010; 298 (02) H331-H339
• 33 Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf 2012; 35 (02) 127-139
• 34 Pinheiro LC, Amaral JH, Ferreira GC. , et al. Gastric S-nitrosothiol formation drives the antihypertensive effects of oral sodium nitrite and nitrate in a rat model of renovascular hypertension. Free Radic Biol Med 2015; 87: 252-262
• 35 Arnelle DR, Stamler JSNO. NO+, NO, and NO- donation by S-nitrosothiols: implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation. Arch Biochem Biophys 1995; 318 (02) 279-285
• 36 Burnley-Hall N, Willis G, Davis J, Rees DA, James PE. Nitrite-derived nitric oxide reduces hypoxia-inducible factor 1α-mediated extracellular vesicle production by endothelial cells. Nitric Oxide 2017; 63: 1-12
• 37 Wang J-M, Wang Y, Huang J-Y. , et al. C-Reactive protein-induced endothelial microparticle generation in HUVECs is related to BH4-dependent NO formation. J Vasc Res 2007; 44 (03) 241-248
• 38 Montoro-García S, Shantsila E, Marín F, Blann A, Lip GY. Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. Basic Res Cardiol 2011; 106 (06) 911-923
• 39 Bundhoo S, Sagan E, James PE, Anderson RA. Clopidogrel results in favourable changes in nitric oxide metabolism in patients undergoing percutaneous coronary intervention. Thromb Haemost 2014; 111 (02) 373-374
• 40 Dangelmaier C, Jin J, Smith JB, Kunapuli SP. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Thromb Haemost 2001; 85 (02) 341-348
• 41 Flaumenhaft R. Molecular basis of platelet granule secretion. Arterioscler Thromb Vasc Biol 2003; 23 (07) 1152-1160
• 42 Arima T, Ohshima Y, Mizuno T, Kitamura Y, Segawa T, Nomura Y. Cyclic GMP elevation by 5-hydroxytryptamine is due to nitric oxide derived from endogenous nitrosothiol in NG108-15 cells. Biochem Biophys Res Commun 1996; 227 (02) 473-478
• 43 Gambaryan S, Geiger J, Schwarz UR. , et al. Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase. Blood 2004; 103 (07) 2593-2600
• 44 Gurbel PA, Tantry US. Drug insight: Clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 2006; 3 (07) 387-395
• 45 Brose KMJ, Lee AYY. Cancer-associated thrombosis: prevention and treatment. Curr Oncol 2008; 15 (Suppl. 01) S58-S67
• 46 Tutuian R, Katz PO, Bochenek W, Castell DO. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Aliment Pharmacol Ther 2002; 16 (04) 829-836
• 47 Shin JS, Lee JY, Cho KH. , et al. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study. Aliment Pharmacol Ther 2014; 40 (05) 548-561
• 48 Gan KH, Geus WP, Lamers CB, Heijerman HG. Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H. pylori-negative healthy subjects. Dig Dis Sci 1997; 42 (11) 2304-2309
• 49 Ghobrial J, Gibson CM, Pinto DS. Delayed clopidogrel transit during myocardial infarction evident on angiography. J Invasive Cardiol 2015; 27 (05) E68-E69